BioSpace News Archive

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the selection of Stephen Harrison, MD as principal investigator of, and key design elements for, its upcoming Ph2a study of NASH drug candidate ALG-055009.

Onkos Surgical announced its launch of the JTS Extendible Prosthesis, a novel growing implant designed for pediatric patients with bone cancer, and unveiled its new, state-of-the-art manufacturing and R&D innovation center at its Parsippany, NJ headquarters to support the integration and growth of the technology.

Gibraltar Industries, Inc. (Nasdaq: ROCK), a leading manufacturer and provider of products and services for the renewable energy, residential, agtech and infrastructure markets, announced today that it expects to release its second quarter 2023 financial results at approximately 7:30 a.m. ET on Wednesday, August 2, 2023.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it has submitted a Clinical Trial Application to initiate a Phase 1/2 clinical trial of OTOF-GT in Europe.

Biophytis SA announced that it has entered into definitive agreements for the purchase and sale of 1,333,334 units, each consisting of one American Depositary Share or one prefunded warrant giving right to one ADS and one warrant to purchase one ADS, at a purchase price of $2.85 per unit comprising an ADS and $2.84 per unit comprising a prefunded warrant.

MindBio Therapeutics Corp. is pleased to have started pre-screening for participant entry into Phase 2 LSD-Microdosing clinical trials.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call to discuss new positive clinical data from the Company’s ongoing Phase I/II BEXMAB study.

Culture Biosciences is excited to welcome Eliana Clark, PhD, Executive Vice President and Chief Technical Officer at Intellia Therapeutics, Inc., to the company’s Advisory Board.

MeMed, a leader in the emerging field of advanced host response technologies, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on whole blood samples on the point-of-need MeMed Key® analyzer to help healthcare providers distinguish between bacterial and viral infections in 15 minutes.

Jnana Therapeutics today announced the appointment of George Vratsanos, M.D., F.A.C.R., to chief medical officer and head of research and development.